Who wants to invest in Chinese biotechnology companies?
Meet TransThera, a Hong Kong biotech company that hasn't even released a paracetamol to the market, but made its investors feel like they had, no less, cracked the code to eternal life!
How? A 4,500% surge since its IPO in July, in just 3 months (!)
And whoever bought at 10? Found themselves at 600!
And all this without a single product on the shelf, not even nose drops...
(Who said you need a product for a multi-billion dollar valuation?)
What goes up without reason, lands without a parachute?
After the frenzy, TransThera returned to reality at dizzying speed...
A drop of over 70% in just a few days!
And whoever entered at the peak?
Was left holding the test tube with a face that said, 'Is there a doctor in the house?'
The reality: no approvals. No sales. No drug.
Only trials... and a lot of hope.
And in the first half of 2025?
Revenue: 0. Profits: 0.
Logic? Not found...
So what did we learn from this clinical trial?
Biotechnology is fascinating, until you get burned.
That the stock market loves dreams, until someone asks, 'Wait a minute, is there even a product...?'
If it goes up for no reason, it can also fall without warning.
And when exactly is a Chinese company with no revenue worth more than an entire hospital...?
So what do you think about the TransThera story?
Medical revolution?
Clinical research at investors' expense?